TRAIL and microRNAs in the treatment of prostate cancer: Therapeutic potential and role of nanotechnology

Applied Microbiology and Biotechnology

Volumn 97, Issue 20, 2013, Pages 8849-8857

  Farooqi, Ammad Ahmad ^a   De Rosa, Giuseppe ^b  

^a RASHID LATIF MEDICAL COLLEGE   (Pakistan)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

miRNA; Nanotechnology; Prostate cancer; Signaling cascades; TRAIL

Indexed keywords

INTRACELLULAR SIGNALING; MIRNA; POST-TRANSCRIPTIONAL REGULATIONS; PROSTATE CANCERS; SIGNALING CASCADES; SPATIOTEMPORAL BEHAVIORS; THERAPEUTIC POTENTIALS; TRAIL;

CELL DEATH; DRUG THERAPY; GENE EXPRESSION; LIGANDS; NANOTECHNOLOGY; RNA; SIGNALING; TISSUE;

DISEASES;

DACTINOMYCIN; DEATH RECEPTOR; DOXORUBICIN; LIPOSOME; MICRORNA; NANOCARRIER; PACLITAXEL; POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER; GENE EXPRESSION; NANOTECHNOLOGY; RNA; SIGNALING;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GENETICS; CANCER INHIBITION; CANCER PATIENT; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; LIPOSOMAL DELIVERY; NANOENCAPSULATION; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; ONCOGENE; PROSTATE CANCER; REVIEW; TARGET CELL DESTRUCTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MICRORNAS; NANOTECHNOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84885374751     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-013-5227-9     Document Type: Review

References (77)

1. Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, Aneja R (2011) Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release 149(3):314-322
2. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ (2012) Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A 109(26):E1695-E1704
3. Bae S, Ma K, Kim TH, Lee ES, Oh KT, Park E-S, Lee KC, Youn YS (2012) Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33(5):1536-1546
4. Basile L, Pignatello R, Passirani C (2012) Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv 9(3):255-268
5. Biray AvcI Ç, Özcan I, BalcI T, Özer Ö, Gündüz C (2013) Design of polyethylene glycol-polyethylenimine nanocomplexes as non-viral carriers: mir-150 delivery to chronic myeloid leukemia cells. Cell Biol Int. doi: 10.1002/cbin.10157
6. Bo Y, Guo G, Yao W (2013) miRNA-mediated tumor specific delivery of TRAIL reduced glioma growth. J Neurooncol 112(1):27-37
7. Boll K, Reiche K, Kasack K, Mörbt N, Kretzschmar A, Tomm J, Verhaegh G, Schalken J, von Bergen M, Horn F (2012) MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 32(3):277-285
8. Cattel L, Ceruti M, Dosio F (2004) From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 16(Suppl 4):94-97
9. Chen J, Yang B, Cheng X, Qiao Y, Tang B, Chen G, Wei J, Liu X, Cheng W, Du P (2012) Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model. Cancer Sci 103(2):325-333
10. Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S, Arora S, Deng G, Shahryari V, Chang I (2013) Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PloS One 8(3):e58929
11. Cruz LJ, Rueda F, Cordobilla B, Simón L, Hosta L, Albericio F, Domingo JC (2011) Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol Pharm 8(1):104-116
12. de Antonellis P, Medaglia C, Cusanelli E, Andolfo I, Liguori L, De Vita G, Carotenuto M, Bello A, Formiggini F, Galeone A, De Rosa G, Virgilio A, Scognamiglio I, Sciro M, Basso G, Schulte JH, Cinalli G, Iolascon A, Zollo M (2011) MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One 6(9): e24584
13. De Miguel D, Basáñez G, Sánchez D, Malo PGN, Marzo I, Larrad L, Naval J, Pardo JN, Anel A, Martinez-Lostao L (2013) Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells. Mol Pharm 10(3):893-904
14. De Rosa G, La Rotonda MI (2009) Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 14(8):2801-2823
15. De Rosa G, De Stefano D, Galeone A (2010) Oligonucleotide delivery in cancer therapy. Expert Opin Drug Deliv 7(11):1263-1278
16. Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W, Ma L, Xiang W, Zhu Q, Liu J (2011) Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine 6:1991-2005
17. Fan H, Hu Q-D, Xu F-J, Liang W-Q, Tang G-P, Yang W-T (2012) In vivo treatment of tumors using host-guest conjugated nanoparticles functionalized with doxorubicin and therapeutic gene pTRAIL. Biomaterials 33(5):1428-1436
18. Farooqi AA, Bhatti S, Ismail M (2012a) TRAIL and vitamins: opting for keys to castle of cancer proteome instead of open sesame. Cancer Cell Int 12(1):22
19. Farooqi AA, Rana A, Riaz AM, Khan A, Ali M, Javed S, Mukhtar S, Minhaj S, Rao JR, Rajpoot J (2012b) NutriTRAILomics in prostate cancer: time to have two strings to one's bow. Mol Biol Rep 39(4):4909-4914
20. Fattal E, De Rosa G (2008) Polymeric nano and microparticles for the delivery of antisense oligonucleotides and SiRNA. In Nancy Smyth Templeton (ed) Gene and cell therapy: therapeutic mechanisms and strategies, 3rd edn. Taylor & Francis Group, CRC, Boca Raton.
21. Gabizon A, Martin F (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Drugs 54(4):15-21
22. Ghosh R, Singh LC, Shohet JM, Gunaratne PH (2013) A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 34(3):807-816
23. Graf N, Bielenberg DR, Kolishetti N, Muus C, Banyard J, Farokhzad OC, Lippard SJ (2012) αvβ3 Integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt (IV) prodrug. ACS Nano 6(5):4530-4539
24. Gu G, Xia H, Hu Q, Liu Z, Jiang M, Kang T, Miao D, Tu Y, Pang Z, Song Q (2013) PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 34(1):196-208
25. Guo L, Fan L, Ren J, Pang Z, Ren Y, Li J, Wen Z, Qian Y, Zhang L, Ma H (2012) Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine 7:1449-1460
26. He L, Yao H, Fan L, Liu L, Qiu S, Li X, Gao J, Hao C (2012) MicroRNA-181b expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3. Genet Mol Res 12(2):1012-1021
27. Holgado MA, Martin-Banderas L, Alvarez-Fuentes J, Fernandez-Arevalo M, Arias JL (2012) Drug targeting to cancer by nanoparticles surface functionalized with special biomolecules. Curr Med Chem 19(19):3188-3195
28. Hu Q, Jiang Q, Jin X, Shen J, Wang K, Li Y, Xu F, Tang G, Li Z (2013) Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 34(9):2265-2276
29. Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S (2013) MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene 32(35):4139-4147
30. Jin H, Yu Y, Chrisler WB, Xiong Y, Hu D, Lei C (2012) Delivery of microRNA-10b with polylysine nanoparticles for inhibition of breast cancer cell wound healing. Breast Cancer (Auckl) 6:9-19
31. Kim JK, Choi K-J, Lee M, M-h J, Kim S (2012a) Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 33(1):207-217
32. Kim K, Chadalapaka G, Pathi SS, Jin U-H, Lee J-S, Park Y-Y, Cho S-G, Chintharlapalli S, Safe S (2012b) Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b- 25 clusters. Mol Cancer Ther 11(9):1852-1862
33. Lee AL, Dhillon SH, Wang Y, Pervaiz S, Fan W, Yang YY (2011a) Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Mol Biosyst 7(5):1512-1522
34. Lee AL, Wang Y, Pervaiz S, Fan W, Yang YY (2011b) Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. Macromol Biosci 11(2):296-307
35. Li L, Xie X, Luo J, Liu M, Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z (2012) Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther 20(12):2326-2334
36. Li T, Li D, Sha J, Sun P, Huang Y (2009) MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun 383(3):280-285
37. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, Chen X, Lee KC (2011) Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 32(13):3538-3546
38. Liu H, Han Y, Fu H, Liu M, Wu J, Chen X, Zhang S, Chen Y (2013) Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli. Appl Microbiol Biotechnol 97(7):2877-2884
39. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1):271-284
40. Majid S, Dar AA, Saini S, Yamamura S, Hirata H, Tanaka Y, Deng G, Dahiya R (2010) MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 116(24):5637-5649
41. Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G, Botti G, Chieffi P, Lamberti M (2012) New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv 30(1):302-309
42. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G (2011) Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 7(6):955-964
43. Moghimi S, Szebeni J (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42(6):463-478
44. Na SJ, Chae SY, Lee S, Park K, Kim K, Park JH, Kwon IC, Jeong SY, Lee KC (2008) Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. Int J Pharm 363(1):149-154
45. Nanta R, Kumar D, Meeker D, Rodova M, Van Veldhuizen P, Shankar S, Srivastava R (2013) NVP-LDE-225 (erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis 2(4):e42
46. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN (2001) Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61(2):759-763
47. Pan G, Ni J, Wei Y-F, G-l Y, Gentz R, Dixit VM (1997a) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277(5327):815-818
48. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997b) The receptor for the cytotoxic ligand TRAIL. Science 276(5309):111-113
49. Pan Y, Jia T, Zhang Y, Zhang K, Zhang R, Li J, Wang L (2012) MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int J Nanomedicine 7:5957-5967
50. Patron JP, Fendler A, Bild M, Jung U, Müller H, Arntzen MØ, Piso C, Stephan C, Thiede B, Mollenkopf H-J (2012) MiR-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis. PLoS One 7(4):e35345
51. Perlstein B, Finniss SA, Miller C, Okhrimenko H, Kazimirsky G, Cazacu S, Lee HK, Lemke N, Brodie S, Umansky F (2013) TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol 15(1):29-40
52. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G (2010) Identification of the miR-106b 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3(117):ra29
53. Reis ST, Pontes-Junior J, Antunes AA, Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR, Nesrallah AJ, Piantino C (2012) miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol 12(1):14
54. Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda M, Leonetti C, Caraglia M, De Rosa G (2011) Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm 403(1):292-297
55. Sanna V, Sechi M (2012) Nanoparticle therapeutics for prostate cancer treatment. Maturitas 73(1):27-32
56. Schneider P, Thome M, Burns K, Bodmer J-L, Hofmann K, Kataoka T, Holler N, Tschopp J (1997) TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7(6):831-836
57. Schramedei K, Mörbt N, Pfeifer G, Läuter J, Rosolowski M, Tomm J, von Bergen M, Horn F, Brocke-Heidrich K (2011) MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 30(26):2975-2985
58. Semple SC, Klimuk SK, Harasym TO, Dos Santos N, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ, Scherrer P (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510(1-2):152-166
59. Seymour L (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9(2):135-187
60. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327):818-821
61. Shi GH, D-w Y, X-d Y, S-l Z, Dai B, H-l Z, Y-j S, Zhu Y, Y-p Z, W-j X (2010) Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 31(7):867-873
62. Shi XB, Xue L, Yang J, Ma A-H, Zhao J, Xu M, Tepper CG, Evans CP, Kung H-J, deVere White RW (2007) An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 104(50):19983-19988
63. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ (2011) miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 71(5):538-549
64. Shukla R, Chanda N, Zambre A, Upendran A, Katti K, Kulkarni RR, Nune SK, Casteel SW, Smith CJ, Vimal J (2012) Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci U S A 109(31):12426-12431
65. Skidan I, Miao B, Thekkedath RV, Dholakia P, Degterev A, Torchilin V (2009) In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL. Drug Deliv 16(1):45-51
66. Sun D, Layer R, Mueller A, Cichewicz M, Negishi M, Paschal B, Dutta A (2013a) Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene. doi: 10.1038/onc.2013.77
67. Sun K, Deng H-J, Lei S-T, Dong J-Q, Li G-X (2013b) miRNA-338-3p suppresses cell growth of human colorectal carcinoma by targeting smoothened. World J Gastroenterol 19(14):2197-2207
68. Sun NF, Q-y M, Tian A-l H, S-y WR-h, Liu Z-x XL (2012a) Nanoliposome-mediated FL/TRAIL double-gene therapy for colon cancer: in vitro and in vivo evaluation. Cancer Lett 315(1):69-77
69. Sun X, Pang Z, Ye H, Qiu B, Guo L, Li J, Ren J, Qian Y, Zhang Q, Chen J (2012b) Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials 33(3):916-924
70. Szlachcic A, Pala K, Zakrzewska M, Jakimowicz P, Wiedlocha A, Otlewski J (2012) FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine 7:5915-5927
71. Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, Prenter S, Harvey H, Domingo-Fernández R, Bray IM (2012) Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One 7(5):e38129
72. Verdoodt B, Neid M, Vogt M, Kuhn V, Liffers S-T, Palisaar R-J, Noldus J, Tannapfel A, Mirmohammadsadegh A (2013) MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int J Oncol 43(1):307-314
73. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16(17):5386-5397
74. Yu R, Mandlekar S, Ruben S, Ni J, Kong AT (2000) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 60(9):2384-2389
75. Zhao Y, Duan S, Zeng X, Liu C, Davies NM, Li B, Forrest ML (2012) Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells. Mol Pharm 9(6):1705-1716
76. Zhao Y, Li Y, Wang L, Yang H, Wang Q, Qi H, Li S, Zhou P, Liang P, Wang Q (2013) microRNA response elements-regulated TRAIL expression shows specific survival-suppressing activity on bladder cancer. J Exp Clin Cancer Res 32(1):10
77. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I (2006) RNAi-mediated gene silencing in non-human primates. Nature 441(7089):111-114